v3.26.1
Segment Information - Schedule of Segment Information, Including Significant Segment Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]    
Revenue $ 70,874 $ 52,443
Cost of revenue 18,708 16,979
Research and development 23,623 24,203
Sales and marketing 26,346 23,047
General and administrative 20,984 17,399
Share-based compensation expense (11,928) (12,147)
Restructuring expense [1] (643) 0
Impairment of long-lived assets [1] (347) 0
Depreciation and amortization expense (3,386) (4,286)
Other unallocated items [2] (7,448) (6,673)
Net loss (20,015) (29,830)
Operating Segments    
Segment Reporting Information [Line Items]    
Revenue 70,874 52,443
Cost of revenue 17,244 15,885
Research and development 23,160 23,647
Sales and marketing 24,742 21,413
General and administrative 12,519 9,502
Items to reconcile net income or net loss to Adjusted EBITDA(3) [3] 14,345 13,940
Adjusted EBITDA [3] 1,778 (9,217)
Operating Segments | MRD    
Segment Reporting Information [Line Items]    
Revenue 67,093 43,721
Cost of revenue 17,244 15,885
Research and development 9,226 9,159
Sales and marketing 24,742 21,413
General and administrative 12,519 9,502
Items to reconcile net income or net loss to Adjusted EBITDA(3) [3] 8,776 8,127
Adjusted EBITDA [3] 12,138 (4,111)
Operating Segments | Immune Medicine    
Segment Reporting Information [Line Items]    
Revenue 3,781 8,722 [2]
Research and development 13,934 14,488 [2]
Items to reconcile net income or net loss to Adjusted EBITDA(3) [3] 5,569 5,813 [2]
Adjusted EBITDA [3] (10,360) (5,106) [2]
Operating Segments | MRD and Immune Medicine    
Segment Reporting Information [Line Items]    
Share-based compensation expense [4] (9,969) (9,654)
Unallocated Corporate    
Segment Reporting Information [Line Items]    
Other segment items [5] 5,776 5,153
Unallocated Corporate | Immune Medicine    
Segment Reporting Information [Line Items]    
Other segment items [5] $ 5,776 $ 5,153 [2]
[1] Represents expenses recognized in conjunction with a restructuring that primarily impacted research and development activities.
[2] Costs related to Digital Biotechnologies, Inc. are no longer included as Immune Medicine costs and have been reclassified to the “other unallocated items” total.
[3] Adjusted EBITDA is a non-GAAP financial measure. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Adjusted EBITDA” for an explanation of how it is calculated and used by management.
[4] Represents share-based compensation expense related to various awards. See Note 11, Equity Incentive Plans for details on our share-based compensation expense.
[5] For the Immune Medicine segment, includes all Immune Medicine operating expenses, other than research and development expenses.